Today: Imprimis Pharmaceuticals Inc. (IMMY) Earns Buy Rating from Analysts at Rodman & Renshaw

Today: Imprimis Pharmaceuticals Inc. (IMMY) Earns Buy Rating from Analysts at Rodman & Renshaw

Research analysts at Rodman & Renshaw began coverage on shares of Imprimis Pharmaceuticals Inc. (NASDAQ:IMMY) in a research note issued to investors on Monday. The brokerage set a “buy” rating and a $5.00 price target on the specialty pharmaceutical company’s stock. Rodman & Renshaw’s price objective would suggest a potential upside of 91.57% from the stock’s current price.

Imprimis Pharmaceuticals (NASDAQ:IMMY) opened at 2.61 on Monday. The stock’s 50 day moving average price is $2.79 and its 200-day moving average price is $3.61. Imprimis Pharmaceuticals has a one year low of $2.22 and a one year high of $7.81. The company’s market capitalization is $34.59 million.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Opaleye Management Inc. increased its position in shares of Imprimis Pharmaceuticals by 1.4% in the second quarter. Opaleye Management Inc. now owns 1,267,500 shares of the specialty pharmaceutical company’s stock worth $4,766,000 after buying an additional 17,500 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Imprimis Pharmaceuticals by 1.7% in the second quarter. Vanguard Group Inc. now owns 168,584 shares of the specialty pharmaceutical company’s stock worth $634,000 after buying an additional 2,831 shares in the last quarter. Granite Investment Partners LLC increased its position in shares of Imprimis Pharmaceuticals by 3.7% in the third quarter. Granite Investment Partners LLC now owns 160,876 shares of the specialty pharmaceutical company’s stock worth $613,000 after buying an additional 5,686 shares in the last quarter. Northern Trust Corp increased its position in shares of Imprimis Pharmaceuticals by 4.1% in the third quarter. Northern Trust Corp now owns 45,467 shares of the specialty pharmaceutical company’s stock worth $173,000 after buying an additional 1,800 shares in the last quarter. Finally, Berson & Corrado Investment Advisors LLC increased its position in shares of Imprimis Pharmaceuticals by 6.4% in the third quarter. Berson & Corrado Investment Advisors LLC now owns 33,097 shares of the specialty pharmaceutical company’s stock worth $126,000 after buying an additional 1,990 shares in the last quarter. Institutional investors and hedge funds own 24.85% of the company’s stock.

About Imprimis Pharmaceuticals

Related posts

Leave a Comment